Is Sanofi Consumer Healthcare India the Best Stock in Its Sector? A Look at the Numbers

Sanofi Consumer Healthcare India CMP Rs 4,017 (16 Sep 2026). Market cap Rs 9,367 Cr. ROE 76.46%. P/E 35.21x versus Industry P/E 51.01x.

Updated: 16 Sept 2026 • 1:27 pm

Posted by:

Is Sanofi Consumer Healthcare India the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Sanofi Consumer Healthcare India is one of the names investors compare when screening the Healthcare sector, built on a 76.46% return on equity and a P/E of 35.21x against an Industry P/E of 51.01x. Sanofi Consumer Healthcare India Ltd markets over-the-counter and consumer health products, demerged from Sanofi India as a separately listed consumer healthcare entity. Whether Sanofi Consumer Healthcare India is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Sanofi Consumer Healthcare India the best stock in its sector? The stock trades on the NSE at Rs 4,017 as of 16 September 2026, within its 52-week range of Rs 3,975.00 to Rs 5,357.00. Sanofi Consumer Healthcare India Ltd markets over-the-counter and consumer health products, demerged from Sanofi India as a separately listed consumer healthcare entity.

Sanofi Consumer Healthcare India sits in the Healthcare sector, and its 76.46% ROE and 35.21x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Sanofi Consumer Healthcare India

Sanofi Consumer Healthcare India Ltd markets over-the-counter and consumer health products, demerged from Sanofi India as a separately listed consumer healthcare entity. At a market capitalisation of Rs 9,367 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Sanofi Consumer Healthcare India the Best Stock in Its Sector?

Sanofi Consumer Healthcare India makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 76.46% ROE with a 35.21x P/E against the sector's 51.01x Industry P/E. Sanofi Consumer Healthcare India's 35.21x P/E is well below the 51.01x Industry P/E despite a 76.46% ROE that is exceptional even within this series, one of the clearer quality-to-valuation gaps among the Healthcare names covered.

Metric	Sanofi Consumer Healthcare India
CMP (NSE)	Rs 4,016.60
52-Week High / Low	Rs 5,357.00 / Rs 3,975.00
Market Cap	Rs 9,367 Cr
P/E (TTM) vs Industry P/E	35.21x vs 51.01x
P/B	26.92
ROE	76.46%
EPS (TTM)	Rs 115.50
Dividend Yield	1.84%
Debt to Equity	0.06

Compare Sanofi Consumer Healthcare India Against Other Healthcare Sector Stocks

How Sanofi Consumer Healthcare India Compares Against Its Healthcare Sector Peers

The table below sets Sanofi Consumer Healthcare India against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Sanofi Consumer Healthcare India	9,367	35.21	76.46%	0.06
Pfizer	18,583	25.28	17.19%	0.02
Abbott India	54,370	33.67	32.51%	0.04
GlaxoSmithKline Pharmaceuticals	48,064	45.00	45.69%	0.01
Peer average (3 companies)	-	34.65	31.80%	0.02

Against this peer set, Sanofi Consumer Healthcare India's 76.46% ROE is above the 31.80% peer average, and its P/E of 35.21x runs above the peer average of 34.65x. Sanofi Consumer Healthcare India's 35.21x P/E is well below the 51.01x Industry P/E despite a 76.46% ROE that is exceptional even within this series, one of the clearer quality-to-valuation gaps among the Healthcare names covered.

What Makes Sanofi Consumer Healthcare India Worth Watching in Healthcare

Exceptionally high ROE: A 76.46% ROE is among the highest in this entire series, reflecting an extremely asset-light consumer healthcare brand model.
Well below Industry P/E: A 35.21x P/E against a 51.01x Industry P/E is a significant discount for a business with this level of profitability.
Near debt free: A debt to equity ratio of 0.06 gives the company almost complete balance sheet flexibility.

Sanofi Consumer Healthcare India Valuation: Is It Justified?

Sanofi Consumer Healthcare India's 35.21x P/E is well below the 51.01x Industry P/E despite a 76.46% ROE that is exceptional even within this series, one of the clearer quality-to-valuation gaps among the Healthcare names covered. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Bata India the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Sanofi Consumer Healthcare India and other Healthcare sector stocks.

How to Track Sanofi Consumer Healthcare India Before You Invest

Before deciding whether Sanofi Consumer Healthcare India deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Sanofi Consumer Healthcare India to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Sanofi Consumer Healthcare India earns a place in the best stock in its sector conversation on the strength of a 76.46% ROE and a P/E of 35.21x against a 51.01x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Sanofi Consumer Healthcare India the best stock in its sector?

Ans. Sanofi Consumer Healthcare India has a 76.46% ROE and trades at 35.21x P/E against a 51.01x Industry P/E, and compares above the peer average ROE of 31.80% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Sanofi Consumer Healthcare India?

Ans. Sanofi Consumer Healthcare India was trading at Rs 4,016.60 on the NSE as of 16 September 2026, within its 52-week range of Rs 3,975.00 to Rs 5,357.00.

What sector does Sanofi Consumer Healthcare India belong to?

Ans. Sanofi Consumer Healthcare India is classified under the Healthcare sector on Univest.

How does Sanofi Consumer Healthcare India compare to its sector peers on P/E?

Ans. Sanofi Consumer Healthcare India's P/E of 35.21x is above the 34.65x average of the 3 named peers compared in this article.

What is Sanofi Consumer Healthcare India's return on equity?

Ans. Sanofi Consumer Healthcare India reported a return on equity of 76.46%, which is above the 31.80% average of its named peers in this comparison.

Should I invest in Sanofi Consumer Healthcare India based on its sector position?

Ans. Sanofi Consumer Healthcare India's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.